Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXACT: XC001 in refractory angina
NCT04125732Phase 2Completed
- Sponsor
- XyloCor Therapeutics
- Start
- Jan 2020
- Primary completion
- Jan 2023
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of encoberminogene rezmadenovec in Angina Pectoris (AP) (4 arms), sponsored by XyloCor Therapeutics. Primary endpoint: Adverse events at 6 months. Started Jan 2020; status: completed.
02
Drugs
encoberminogene rezmadenovec
03
Conditions
Angina Pectoris (AP)
Beyond the preview
Go deeper on NCT04125732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04125732.